Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Cash from Investing Activities (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Cash from Investing Activities for 3 consecutive years, with $15.4 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash from Investing Activities fell 48.58% year-over-year to $15.4 million, compared with a TTM value of $105.8 million through Dec 2024, up 244.88%, and an annual FY2024 reading of $105.8 million, up 244.88% over the prior year.
  • Cash from Investing Activities was $15.4 million for Q4 2024 at Oramed Pharmaceuticals, up from -$34.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $94.7 million in Q2 2024 and bottomed at -$75.1 million in Q3 2023.
  • Average Cash from Investing Activities over 3 years is $5.2 million, with a median of $8.9 million recorded in 2022.
  • The sharpest move saw Cash from Investing Activities crashed 6212.45% in 2023, then skyrocketed 743.47% in 2024.
  • Year by year, Cash from Investing Activities stood at $11.3 million in 2022, then surged by 166.4% to $30.0 million in 2023, then crashed by 48.58% to $15.4 million in 2024.
  • Business Quant data shows Cash from Investing Activities for ORMP at $15.4 million in Q4 2024, -$34.3 million in Q3 2024, and $94.7 million in Q2 2024.